Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 1/20 | 0.40 |
| ▸ | METTL14 | Q9HCE5 | 1/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADK | P55263 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19859745 | 0.91 | PRMT5 (0.38) | METTL3METTL14PRMT5WDR77ADK | |
| SCHEMBL3229893 | 0.87 | PRMT5 (0.50) | METTL3PRMT5WDR77ADORA2AADK | |
| SCHEMBL19537076 | 0.87 | PRMT5 (0.50) | METTL3PRMT5WDR77ADORA2AADK | |
| SCHEMBL1736124 | 0.87 | PRMT5 (0.50) | METTL3PRMT5WDR77ADORA2AADK | |
| SCHEMBL3232370 | 0.87 | ADORA2A (0.39) | METTL3METTL14PRMT5WDR77ADORA2A | |
| SCHEMBL3234238 | 0.87 | PRMT5 (0.50) | METTL3PRMT5WDR77ADORA2AADK | |
| SCHEMBL19535607 | 0.87 | PRMT5 (0.50) | METTL3PRMT5WDR77ADORA2AADK | |
| SCHEMBL17109566 | 0.87 | PRMT5 (0.50) | METTL3PRMT5WDR77ADORA2AADK | |
| SCHEMBL21006387 | 0.87 | PRMT5 (0.50) | METTL3PRMT5WDR77ADORA2AADK | |
| SCHEMBL16373988 | 0.87 | PRMT5 (0.50) | METTL3PRMT5WDR77ADORA2AADK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115916217-A | Alkynyl nucleoside analogs for the treatment of hepatitis E | 杨森制药公司 | 2023-04-04 | — | — | CN | disclosed |
| WO-2021209425-A9 | ALKYNYL NUCLEOSIDE ANALOGS FOR TREATMENT OF HEPATITIS E | Janssen Pharmaceuticals, Inc. (US) | 2022-12-22 | — | — | WO | disclosed |
| EP-3497111-A2 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen BioPharma, Inc. (US) | 2019-06-19 | — | — | EP | disclosed |
| US-20190169221-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2019-06-06 | — | — | US | disclosed |
| US-20190169221-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2019-06-06 | — | — | US | disclosed |
| WO-2018031818-A2 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2018-02-15 | — | — | WO | disclosed |
| US-8278282-B2 | Nucleoside analogs for treatment of viral infections | NOVARTIS AG (CH) | 2012-10-02 | — | — | US | disclosed |
| US-8278282-B2 | Nucleoside analogs for treatment of viral infections | NOVARTIS AG (CH) | 2012-10-02 | — | — | US | disclosed |
| US-8278282-B2 | Nucleoside analogs for treatment of viral infections | NOVARTIS AG (CH) | 2012-10-02 | — | — | US | disclosed |
| EP-2132216-B1 | NOVEL NUCLEOSIDE ANALOGS FOR TREATMENT OF VIRAL INFECTIONS | NOVARTIS PHARMA AG (CH) | 2011-11-16 | — | — | EP | disclosed |
| WO-2011131167-A2 | BISTABLE MAGNETIC ACTUATOR | JOHNSON ELECTRIC DRESDEN GMBH (DE) | 2011-10-27 | — | — | WO | disclosed |
| US-20100227833-A1 | NOVEL NUCLEOSIDE ANALOGS FOR TREATMENT OF VIRAL INFECTIONS | NOVARTIS PHARMA AG (CH) | 2010-09-09 | — | — | US | disclosed |
| US-20100227833-A1 | NOVEL NUCLEOSIDE ANALOGS FOR TREATMENT OF VIRAL INFECTIONS | NOVARTIS PHARMA AG (CH) | 2010-09-09 | — | — | US | disclosed |
| US-20100227833-A1 | NOVEL NUCLEOSIDE ANALOGS FOR TREATMENT OF VIRAL INFECTIONS | NOVARTIS PHARMA AG (CH) | 2010-09-09 | — | — | US | disclosed |
| US-20100144655-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-06-10 | — | — | US | disclosed |
| EP-2132216-A1 | NOVEL NUCLEOSIDE ANALOGS FOR TREATMENT OF VIRAL INFECTIONS | Novartis Pharma AG. (CH) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008095993-A1 | NOVEL NUCLEOSIDE ANALOGS FOR TREATMENT OF VIRAL INFECTIONS | NOVARTIS AG (CH) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008095993-A1 | NOVEL NUCLEOSIDE ANALOGS FOR TREATMENT OF VIRAL INFECTIONS | NOVARTIS AG (CH) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227833-A1 | NOVEL NUCLEOSIDE ANALOGS FOR TREATMENT OF VIRAL INFECTIONS | MAVS, HAVCR2, SAMHD1 | METTL3 380/4885METTL14 918/4885PRMT5 1421/4885 |
| US-20190169221-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | METTL3 153/4885METTL14 307/4885PRMT5 2886/4885 |
| US-20100144655-A1 | ORGANIC COMPOUNDS | OAT, MAVS, HAVCR2 | METTL3 558/4885METTL14 2027/4885PRMT5 1914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.